2011
The approval of ipilimumab-the first in class immune checkpoint inhibitor-in 2011 serves as a landmark period of time in the resurgence of cancer immunotherapy.
Prenatal myelomeningocele (MMC) repair has significant advantages over postnatal repair, as was demonstrated by the Management of Myelomeningocele Study (MOMS) in 2011 1)
Pipeline endovascular device in 2011.
Guidelines for the determination of brain death in infants and children endorsed by the Society of Critical Care Medicine, The Section for Critical Care and Section of Neurology of the American Academy of Pediatrics and the American College of Critical Care Medicine 2).
The Diagnostic Methods commission of the International League against Epilepsy (ILAE) released a first international consensus classification of Focal Cortical Dysplasia (FCD) in 2011.
The 2011 American Heart Association guidelines recommend open surgery or endovascular intervention to treat symptomatic ischemic lesions affecting the anterior cerebral circulation caused by Common carotid artery occlusion 3)
In March 2011, investigators from Australia and several other countries published the results of the DECRA trial in the New England Journal of Medicine. This was a randomized trial comparing decompressive craniectomy to best medical therapy run between 2002 and 2010 to assess the optimal management of patients with medically refractory ICP following diffuse non-penetrating head injury. The study investigators found that decompressive craniectomy was associated with worse functional outcomes, as measured by a standard metric, than best medical care. There were no differences in deaths between groups 4).
InTBIR is a collaborative effort of the European Commission (EC), the Canadian Institutes of Health Research (CIHR) and the National Institutes of Health (NIH). It was set up in October 2011 to advance clinical traumatic brain injury (TBI) research, treatment and care.
Cattle encephalon glycoside and ignotin injection (drug approval H22025046; Jilin Sihuan Pharmaceutical Co. LTD., Jilin, People’s Republic of China) was approved by the Chinese Food and Drug Administration in 2011.